LXG6403

Description

LXG6403 is an orally active and irreversible LOX inhibitor IC50 = 1.3 ?M . LXG6403 is 3.5-fold more specific for LOX than LOXL2 and does not inhibit LOXL1. LXG6403 inhibits FAK signaling and induces ROS generation and DNA damage, leading to G1 arrest and apoptosis in chemoresistant triple-negative breast cancer TNBC cell lines. LXG6403 alters the extracellular matrix ECM and collagen structure, reducing collagen cross-linking and deposition, thereby increasing drug penetration and reducing tumor stiffness. LXG6403 overcomes Doxorubicin HY-15142 resistance in chemoresistant TNBC PDX in vivo and can be used to study high-stiffness resistant tumors.